145 related articles for article (PubMed ID: 27922818)
1. Age-related changes in the gene expression profile of antigen-specific mouse CD8+ T cells can be partially reversed by blockade of the BTLA/CD160 pathways during vaccination.
Dawany N; Parzych EM; Showe LC; Ertl HC
Aging (Albany NY); 2016 Nov; 8(12):3272-3297. PubMed ID: 27922818
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway.
DiMenna L; Latimer B; Parzych E; Haut LH; Töpfer K; Abdulla S; Yu H; Manson B; Giles-Davis W; Zhou D; Lasaro MO; Ertl HC
J Immunol; 2010 May; 184(10):5475-84. PubMed ID: 20410485
[TBL] [Abstract][Full Text] [Related]
3. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
5. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
6. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
8. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.
Lasaro MO; Sazanovich M; Giles-Davis W; Mrass P; Bunte RM; Sewell DA; Hussain SF; Fu YX; Weninger W; Paterson Y; Ertl HC
Mol Ther; 2011 Sep; 19(9):1727-36. PubMed ID: 21587210
[TBL] [Abstract][Full Text] [Related]
9. CD160 serves as a negative regulator of NKT cells in acute hepatic injury.
Kim TJ; Park G; Kim J; Lim SA; Kim J; Im K; Shin MH; Fu YX; Del Rio ML; Rodriguez-Barbosa JI; Yee C; Suh KS; Kim SJ; Ha SJ; Lee KM
Nat Commun; 2019 Jul; 10(1):3258. PubMed ID: 31332204
[TBL] [Abstract][Full Text] [Related]
10. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
[TBL] [Abstract][Full Text] [Related]
11. Characterization of murine CD160+ CD8+ T lymphocytes.
Tsujimura K; Obata Y; Matsudaira Y; Nishida K; Akatsuka Y; Ito Y; Demachi-Okamura A; Kuzushima K; Takahashi T
Immunol Lett; 2006 Jul; 106(1):48-56. PubMed ID: 16764942
[TBL] [Abstract][Full Text] [Related]
12. Hepatic expansion of virus-specific CD8
Wang H; Wu B; Li L; Hu L; Lin J; Jiang C; Cai G; Shen Q
Cell Immunol; 2017 Jan; 311():36-45. PubMed ID: 27743606
[TBL] [Abstract][Full Text] [Related]
13. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
Viganò S; Banga R; Bellanger F; Pellaton C; Farina A; Comte D; Harari A; Perreau M
PLoS Pathog; 2014 Sep; 10(9):e1004380. PubMed ID: 25255144
[TBL] [Abstract][Full Text] [Related]
14. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
15. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
16. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.
Pombo C; Wherry EJ; Gostick E; Price DA; Betts MR
J Infect Dis; 2015 Nov; 212(9):1376-86. PubMed ID: 25883386
[TBL] [Abstract][Full Text] [Related]
17. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
[TBL] [Abstract][Full Text] [Related]
18. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
20. [CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection].
Wang L; Xu X; Feng G; Zhang X; Wang F
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1559-62. PubMed ID: 25146744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
